[HTML][HTML] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Several randomized controlled trials have suggested that adjuvant epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were associated with …
EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled …
JX Wu, Q He, F Ye, QX Zhou, HJ Chen… - OncoTargets and …, 2018 - Taylor & Francis
Purpose The great efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been
identified in patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR …
identified in patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR …
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations
W Tang, X Li, X Xie, X Sun, J Liu, J Zhang, C Wang… - Lung Cancer, 2019 - Elsevier
Objectives Cisplatin-based chemotherapy as an adjuvant therapy for resected non-small cell
lung cancer (NSCLC) has reached its plateau, and it is limited by a high risk of recurrence …
lung cancer (NSCLC) has reached its plateau, and it is limited by a high risk of recurrence …
[HTML][HTML] A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer
R Cui, C Wei, X Li, O Jiang - Medicine, 2022 - journals.lww.com
Background: The role of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor
(TKIs) in improving the prognostic outcome of non-small cell lung cancer (NSCLC) cases …
(TKIs) in improving the prognostic outcome of non-small cell lung cancer (NSCLC) cases …
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in the adjuvant setting for patients with resected epidermal growth factor receptor mutant non …
Q Yin, X Xun, G Yang, H Cui, H Liu - Oncology Research and Treatment, 2021 - karger.com
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
recently become the standard first-line therapy for advanced non-small cell lung cancer …
recently become the standard first-line therapy for advanced non-small cell lung cancer …
[HTML][HTML] Adjuvant EGFR-TKIs for patients with resected EGFR-mutant non-small cell lung cancer: a meta-analysis of 1,283 patients
RL Chen, LL Sun, Y Cao, HR Chen, JX Zhou… - Frontiers in …, 2021 - frontiersin.org
Background Cisplatin-based chemotherapy was previously considered as the standard
adjuvant therapy for improved overall survival (OS) in patients with non-small cell lung …
adjuvant therapy for improved overall survival (OS) in patients with non-small cell lung …
[引用][C] What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non–Small-Cell Lung Cancer
SY Liu, JT Zhang, YL Wu - Journal of Clinical Oncology, 2022 - ascopubs.org
Since 2017, when the ADJUVANT-CTONG1104 (Gefitinib Versus Vinorelbine/Platinum as
Adjuvant Treatment in Stage II-IIIA (N1-N2) NSCLC With EGFR Mutation) trial first reported …
Adjuvant Treatment in Stage II-IIIA (N1-N2) NSCLC With EGFR Mutation) trial first reported …
Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis
M Li, X Hou, S Lin, L Zheng, J Liang, J Chen… - Future …, 2022 - Future Medicine
Background: The role of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in resected EGFR-
mutated non-small-cell lung cancer (NSCLC) remains unclear. Materials & methods: We …
mutated non-small-cell lung cancer (NSCLC) remains unclear. Materials & methods: We …
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer
H Cheng, XJ Li, XJ Wang, ZW Chen, RQ Wang… - Lung Cancer, 2019 - Elsevier
Objectives We performed this meta-analysis to compare adjuvant EGFR-TKIs with a placebo
or adjuvant chemotherapy among patients with resected non-small cell lung cancer …
or adjuvant chemotherapy among patients with resected non-small cell lung cancer …
Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non–Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta …
J Raphael, M Vincent, G Boldt, PS Shah… - American Journal of …, 2019 - journals.lww.com
The role of adjuvant tyrosine kinase inhibitors (TKIs) in non–small cell lung cancer (NSCLC)
is not well defined. Recent randomized controlled trials showed a disease-free survival …
is not well defined. Recent randomized controlled trials showed a disease-free survival …